You are here: Industry Insights > Synairgen

News List

Synairgen Partners with Ashfield Engage to Support the Commercialization of SNG001 contractpharma
January 06, 2022
Aims to bring innovative potential treatment to COVID-19 patients.
Synairgen’s inhaled COVID-19 treatment included in US trial pharmatimes
February 25, 2021
Synairgen’s inhaled interferon beta-1a treatment, SNG001, has been selected for inclusion in the US government-funded ACTIV-2 trial in COVID-19 outpatients.
Synairgen begins large-scale trial of inhaled COVID-19 treatment pharmatimes
January 14, 2021
Southampton, UK-headquartered company Synairgen has treated the first patient in the UK as part of a global Phase III trial evaluating its inhaled COVID-19 treatment SNG001 in hospitalised patients.
Inhaled interferon beta therapy shows promise in COVID-19 trial europeanpharmaceuticalreview
July 21, 2020
SNG001 diminished the risk of COVID-19 patients developing severe symptoms, reduced breathlessness and improved recovery rates.
Synairgen's SNG001 shows strong promise in COVID-19 trial pharmatimes
July 20, 2020
Southampton, UK-based Synairgen has announced positive results from a clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients.
CanSinoBIO, Synairgen get regulatory approval for Covid-19 trials pharmaceutical-technology
March 20, 2020
China-based CanSino Biologics has received regulatory approval to conduct Phase I clinical trial of recombinant novel coronavirus vaccine (adenovirus type 5 vector) candidate.